UPDATE: After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimabnews2022-03-30T21:50:21+00:00March 30th, 2022|FierceBiotech|
An FDA panel reviewing Amylyx’s ALS drug was moved by patient testimony—but they voted it down anywaynews2022-03-30T20:26:42+00:00March 30th, 2022|FierceBiotech|
2 gene editing biotechs team up to improve on delivery with $45 upfrontnews2022-03-30T20:08:21+00:00March 30th, 2022|FierceBiotech|
2 gene editing biotechs team up to improve on delivery with $45M upfrontnews2022-03-30T20:08:21+00:00March 30th, 2022|FierceBiotech|
EU regulators warn clinical trial changes ‘unavoidable’ in Ukraine due to Russian invasionnews2022-03-30T18:34:01+00:00March 30th, 2022|FierceBiotech|
Athira drama not over yet, as investor and ally of former CEO calls for another C-suite changenews2022-03-30T17:19:43+00:00March 30th, 2022|FierceBiotech|
GSK, CureVac hope 2nd time’s the charm as updated COVID vax launches into clinicnews2022-03-30T14:45:23+00:00March 30th, 2022|FierceBiotech|
Top Ginkgo execs each nab $364M pay packages thanks to 2021 SPAC dealnews2022-03-30T13:59:58+00:00March 30th, 2022|FierceBiotech|
UPDATE: Top Ginkgo execs each nab $364M pay packages thanks to 2021 SPAC dealnews2022-03-30T13:59:58+00:00March 30th, 2022|FierceBiotech|
Adagio knows its COVID-19 antibody works against old variants. Can it win EUA in the era of omicron?news2022-03-30T12:03:10+00:00March 30th, 2022|FierceBiotech|
